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Background: Colorectal cancer (CRC) is the third most common cancer diagnosis in 
the Western world.
Aim: To evaluate exhaled volatile organic compounds (VOCs) as a non-invasive 
biomarker for the detection of CRC and precursor lesions using an electronic 
nose.
Methods: In this multicentre study adult colonoscopy patients, without inflammatory 
bowel disease or (previous) malignancy, were invited for breath analysis. Two-thirds 
of the breath tests were randomly assigned to develop training models which were 
used to predict the diagnosis of the remaining patients (external validation). In the 
end, all data were used to develop final-disease models to further improve the dis-
criminatory power of the algorithms.
Results: Five hundred and eleven breath samples were collected. Sixty-four patients 
were excluded due to an inadequate breath test (n = 51), incomplete colonoscopy 
(n = 8) or colitis (n = 5). Classification was based on the most advanced lesion found; 
CRC (n = 70), advanced adenomas (AAs) (n = 117), non-advanced adenoma (n = 117), 
hyperplastic polyp (n = 15), normal colonoscopy (n = 125). Training models for CRC 
and AAs had an area under the curve (AUC) of 0.76 and 0.71 and blind validation re-
sulted in an AUC of 0.74 and 0.61 respectively. Final models for CRC and AAs yielded 
an AUC of 0.84 (sensitivity 95% and specificity 64%) and 0.73 (sensitivity and speci-
ficity 79% and 59%) respectively.
Conclusions: This study suggests that exhaled VOCs could potentially serve as a non-
invasive biomarker for the detection of CRC and AAs. Future studies including more 
patients could further improve the discriminatory potential of VOC analysis for the 
detection of (pre-)malignant colorectal lesions. (https ://clini caltr ials.gov Identifier 
NCT03488537)
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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1  | INTRODUC TION
Colorectal cancer (CRC) is the third most common cancer diagnosis 
and a major cause of mortality in the Western World.1-3 CRC usually 
develops from focal changes within benign polyps via a multistep 
process involving a series of genetic, histological and morphological 
changes that accumulate over time.4 This dwell time allows for early 
detection and removal of precursor lesions to prevent development 
of CRC. Moreover, detection of early-stage CRC improves survival 
rates which is why screening programs for CRC are increasingly 
adapted worldwide.5,6
Nowadays, several CRC screening modalities are available, and 
each test has its own performance characteristics and acceptability 
profile. Preferably, a screening test should be affordable, non-invasive 
and precise to achieve a high rate of cooperation from asymptomatic 
individuals. Faecal immunochemical testing (FIT) is currently the most 
commonly used non-invasive screening test for CRC. This stool-based 
test is relatively cheap and easy to perform, but population screening 
with FIT results in missed cancers and unnecessary colonoscopy pro-
cedures due to suboptimal sensitivity and specificity of 56%-89% and 
92%-97% respectively, for detection of CRC.7-9 Furthermore, ideally 
a screening test should detect treatable precursor lesions to prevent 
development of cancer, but sensitivity of FIT for advanced adenomas 
(AAs) is low, only 39%-57%.7,8 These suboptimal test characteristics 
of FIT and sometimes disappointing adherence rates to FIT screen-
ing programs (37%-62%) illustrate the need for a new, more accurate, 
non-invasive diagnostic test for CRC and its precursor lesions.10-13
Analysis of volatile organic compounds (VOCs) might be a promis-
ing new technique for early detection and surveillance of various dis-
eases, including CRC. VOCs are gaseous carbon-based end products of 
physiologic and pathologic metabolic processes which can be detected 
in all biological specimens (eg breath, saliva, urine, faeces, blood).14,15 It 
has been shown that VOC concentration profiles and/or VOC compo-
sition differ between patients with and without certain diseases, rang-
ing from infectious diseases16,17 to malignancies.18-20 Some potential 
CRC-associated VOCs have already been identified in small pilot stud-
ies,21-35 but the VOCs identified differed among studies and (external) 
validation of the results is lacking. Data on VOC's associated with col-
orectal polyps is even more scarce.25,29,32,33
Thus far, most studies that evaluated the potential of VOCs to 
serve as a non-invasive biomarker for CRC used faecal samples and 
gas chromatography-mass spectrometry (GC-MS) for VOC analysis. 
We hypothesised that breath analysis with electronic nose (e-nose) 
technology may be more suitable for clinical practice since breath 
sampling may be more acceptable for (asymptomatic) individuals. In 
addition, contrary to GC-MS, e-nose technology is relatively low-
cost, easily operated and it allows for point-of-care diagnosis.
Therefore, the objective of this study was to evaluate if exhaled 
VOCs can serve as a non-invasive biomarker for CRC and its precur-
sor lesions using e-nose technology. In this study, breath analysis 
was performed with Aeonose devices (The eNose Company). This 
specific type of e-nose allows for datasets of multiple devices to 
be combined which facilitates the generation of large data sets to 
develop disease models. Furthermore, once-developed models can 
be transferred to new e-noses which will further aid in clinical imple-
mentation of e-nose technology.36
2  | MATERIAL S AND METHODS
2.1 | Protocol and registration
The study protocol was approved by the ethics committee of 
Enschede, the Netherlands, and thereafter by the local ethics com-
mittees of the participating centres. This study was performed in 
compliance with the Declaration of Helsinki and registered at https 
://clini caltr ials.gov (Identifier NCT03488537). All study patients 
provided written informed consent before breath testing.
2.2 | Study design and population
This cross-sectional, proof-of-principle study was conducted in two 
secondary care hospitals in the Netherlands (Medisch Spectrum 
Twente, Enschede and Bernhoven, Uden). All adult patients re-
ferred for elective colonoscopy were invited for study participation. 
Patients with known inflammatory bowel disease (IBD) or (previous) 
malignancy were excluded (not including basal cell carcinoma or 
squamous cell carcinomas of the skin) from breath testing.
2.3 | Breath test
All members of the research team attended a training session for 
study instructions and e-nose training before the start of the study. 
Patients were invited for breath testing during a pre-colonoscopy 
consultation and/or on the day of the examination just before the 
colonoscopy procedure. Some patients performed two breath tests; 
one before and one after bowel preparation to evaluate the influ-
ence of bowel preparation on VOC profiles. Baseline characteristics 
were collected from all eligible patients by research nurses using 
standardised forms for patient interviews and by evaluation of their 
medical records.
Five e-noses were used for breath testing and all tests were 
performed in the same room at each hospital location (Figure 1). 
Patients were instructed to breathe into an e-nose for five consec-
utive minutes using a disposable mouthpiece while wearing a nose 
clip. Failed breath tests were excluded from analysis and the reason 
for exclusion was documented by the research nurse.
2.4 | Aeonose
In this study, breath analysis was performed with Aeonose de-
vices (The eNose Company), which are portable, battery-powered 
devices, that contain three metal-oxide sensors (AMS AG) with 
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different material properties. VOCs present in exhaled breath cause 
redox-reactions at the sensor surfaces of the e-nose which results 
in conductivity changes that are measured and analysed. VOCs in-
teract competitively with these sensors, depending on the physical 
and chemical characteristics of the sensor material. As the reaction 
kinetics are temperature-dependent, the metal-oxide sensors of 
the device are guided through a sinusoidal temperature profile to 
optimise the amount of information gathered from exhaled breath. 
Basically, in this way a virtual sensor array is built mimicking identical 
sensors at different temperatures.37 During each cycle, conductivity 
is measured 32 times. In the end, all conductivity values are com-
bined to represent the composition of the total VOC mixture, called 
a “breathprint”, and each breathprint consists of approximately 7000 
conductivity values.
Breath analysis with this e-nose takes 15 minutes in which the pa-
tient breathes into the device for 5 minutes. Inhaled air is filtered by 
two carbon filters to minimise contamination of the measurements 
by environmental VOCs and the mouthpiece has a High Efficiency 
Particulate Air filter (HEPA; 3M) that prevents contamination of the 
e-nose by bacteria or viruses.
2.5 | Endoscopic evaluation (reference test)
Patients received bowel preparation prior to colonoscopy. The bowel 
preparation prescribed was left to the discretion of the treating 
physician. Colonoscopy data and histopathology reports were evalu-
ated for the presence and size of colorectal lesions. Patients were 
categorised into one of the following subgroups; controls (patients 
without any colonic neoplasia or other abnormality), hyperplastic 
polyps (HPs), non-NAs, AAs (polyps ≥10 mm, >25% villous pathol-
ogy or high-grade dysplasia) or CRC. If multiple neoplastic lesions 
were present, classification was based on the most advanced lesion 
found. All diagnoses were double checked by two members of the 
research team.
Patients with an incomplete colonoscopy procedure, poor bowel 
preparation (Boston Bowel Preparation Score [BBPS] <6) or new di-
agnosis of colitis were excluded from analysis.
2.6 | Blinding
Patients, endoscopists and pathologists remained blinded for the 
outcome of the breath test throughout the study.
2.7 | Study outcomes
The primary outcome was the ability of the e-nose to distinguish 
patients with CRC from controls based on VOC patterns. Secondary 
outcomes included the ability of the e-nose to distinguish patients 
with precursor lesions (AAs, NAs, HPs) from CRC and controls. In 
addition, the effect of bowel preparation on VOC patterns was 
explored.
2.8 | Power calculation
The nature of the statistical method used in e-nose technology 
makes an exact sample size calculation impossible. Previous stud-
ies conducted with this specific e-nose technology have suggested 
that at least 25 cases and 25 control patients are required to build 
a disease-specific model.38-47 For this study, we therefore aimed to 
include at least 60 patients with CRC; 40 CRC patients to develop a 




Data on demographic and baseline characteristics were summarised 
for continuous variables, in case of normal distribution by mean and 
standard deviation, and in case of nonnormal distribution by median 
and interquartile range. For each subgroup (eg HP, NA, AA, CRC), 
data were compared with control patients to detect significant 
differences in baseline characteristics using either the independ-
ent sample t-test (normal distribution) or Mann-Whitney U test 
F I G U R E  1   Electronic nose used in the study; the Aeonose (The 
eNose Company). Patients inhale through a carbon filter to prevent 
the entry of nonfiltered environmental air and breathe into the 
device through a disposable mouthpiece while wearing a nose clip
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(nonnormal distribution) for continuous variables and a chi-squared 
test for categorical data. A two-sided P < 0.05 was considered sta-
tistically significant.
Data analysis of the baseline characteristics was performed by 
using the Statistical Program for the Social Sciences (spss) version 
22.0.
2.9.2 | VOC analysis
Machine Learning was applied to distinguish between breath pro-
files of controls and patients with (pre-)cancerous lesions. During 
each breath measurement 64 × 36 × 3 data points were recorded. 
Strict temperature controls of the sensors limits variability between 
sensors of different devices.36 Potential small differences are tack-
led by pre-treatment of the data including standardisation.48 After 
pre-processing, data were compressed using a Tucker3-like solu-
tion which resulted in a single vector of limited size per partici-
pant.49 Together with the disease diagnosis, the vector was used 
to train an artificial neural network. Using the data analysis pack-
age Aethena (The eNose Company) several permutations of data 
pre-processing, sensor combinations, vector lengths and network 
topologies were investigated to optimise results. More details on 
the data analysis have been published elsewhere.48
2.9.3 | Primary outcome
Breath sample analysis was performed in three phases for CRC ver-
sus controls. Only breath tests conducted before bowel preparation 
were used for these analyses.
• Phase 1: Training models: Development of disease-specific train-
ing models.
An important aspect of e-nose technology is that the artificial neural 
network used to analyse breath tests first needs to be trained to 
recognise disease-specific mixtures of VOCs. Two-thirds of the 
breath tests were used to develop “training models” which were 
validated in the remaining data (phase II). Breath samples were 
randomly assigned to either the “training” or “validation” phase. 
The artificial neural network was trained using the “leave-10%-
out” cross validation technique to verify that training was suc-
cessfully applied at the disease classification, and not on some 
artefact.
• Phase 2: External validation: Blind validation of the disease-spe-
cific training models.
After training, the artificial neural network-parameters were fixed 
and used to blindly predict patient diagnosis of the remaining pa-
tients to validate the diagnostic accuracy of the disease-specific 
training models.
• Phase 3: Final models: Development of final disease-specific 
models.
Another important aspect of e-nose technology is that the diagnos-
tic accuracy of an artificial neural network generally improves 
when more data become available for training until a certain level 
of stability is reached. Therefore, after the validation phase, all 
data was made available to further train the artificial neural net-
work using the “leave-10%-out” cross validation technique.
2.10 | Secondary outcomes
The three phases described above were also followed to develop 
algorithms to differentiate between AAs and controls. For all other 
secondary outcomes only final disease models were developed 
(phase III) because we only aimed to explore if VOC analysis could be 
used to differentiate between these subgroups. Again, only breath 
tests conducted before bowel preparation were used for model de-




Breath samples of 511 patients were collected over a study pe-
riod of 10 months. Sixty-four patients were excluded due to a 
failed breath test (n = 51), incomplete colonoscopy (n = 8) or 
newly diagnosed colitis (n = 5). Of the 447 patients remaining 
patients 58.8% were male with a mean age of 65 years (stand-
ard deviation [SD] 9.0). Most patients included were referred 
for CRC screening through the Dutch population screening pro-
gram (63.5%), followed by diagnostic colonoscopy (24.2%) and 
surveillance colonoscopy (12.3%). Adequate bowel preparation 
was achieved in all patients after 3 days of dietary restrictions 
and a split-dose of either 2L Moviprep or 4L Klean-prep. Seventy 
patients were diagnosed with CRC, 117 with one or more AAs, 
117 with NAs, 15 with HPs and 128 had normal colonoscopy 
(Figure 2).
Baseline characteristics were categorised per outcome and are 
shown in Table 1. All groups showed a male sex predominance and 
controls were slightly younger (P < 0.05) than patients with neoplas-
tic lesions.
3.2 | CRC versus controls
Breath tests of 42 CRC patients and 68 control patients were used 
to train an artificial neural network to recognise CRC specific VOC 
mixtures. This training model for CRC had an Area under the curve 
(AUC) of 0.76, with a sensitivity of 83% and specificity of 60% and 
this model was able to predict patient diagnosis of the blinded pa-
tients with similar results, AUC of 0.74. The final model for CRC had 
an AUC of 0.84, with a sensitivity of 95% and specificity of 64%. 
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(Table 2; Figure 3) Baseline characteristics of the development group 
and validation group did not differ significantly (data not shown).
3.3 | AAs versus controls
The training model for AAs had an AUC of 0.71 with a sensitivity of 
82% and a specificity of 59%. Accuracy of this model was slightly lower 
in the validation group, AUC of 0.61. The final model for AAs versus 
control had an AUC of 0.73, with a sensitivity of 79% and a specificity 
of 59% (Table 2). Baseline characteristics of the development group 
and validation group did not differ significantly (data not shown).
3.3.1 | Correctly versus incorrectly 
predicted patients
Baseline characteristics such as age, gender, body mass index 
(BMI), co-morbidities, fasting meal and use of antibiotics or pro-
ton pomp inhibitors (PPI) were not significantly different between 
correctly and incorrectly predicted patients (Table 3). In addition, 
time of measurement did not significantly influence accuracy of 
the blind predictions. CRC predictions were slightly better in the 
first half (P = 0.38) while predictions of AAs were more accurate 
in the second half (P = 0.10). Control patients with a history of 
polypectomy (n = 10) were misclassified as AA in 20% (false posi-
tives, P = 0.32).
3.4 | Secondary outcomes
All final disease models for secondary outcomes (except for AAs 
versus controls) are shown in Table 4. The e-nose was able to differ-
entiate between CRC and NAs with an AUC of 0.85, but was unable 
to differentiate between CRC and AAs. The e-nose was also able to 
distinguish patients with CRC and AAs from controls (AUC of 0.72), 
but VOC profiles of AAs and NAs were too similar. In addition, the 
e-nose was unable to distinguish patients with adenomatous polyps 
(NA + AA) from controls.
With regards to bowel preparation; 207 patients performed a 
breath test before and after bowel preparation. Four patients diag-
nosed with AAs failed their second breath tests. These patients were 
therefore excluded from this specific analysis. The e-nose was able 
to differentiate between all patients before and after bowel prepa-
ration, AUC of 0.72. Analysis of breath tests before and after bowel 
preparation within subgroups yielded an AUC of 0.82 for controls 
and 0.70 for AAs. Only 19 CRC patients performed a breath test 
before and after bowel preparation which was too little for analysis.
4  | DISCUSSION
This multicentre study suggests that breath analysis with e-nose 
technology could become a promising, non-invasive, diagnostic tool 
for the detection of CRC. The e-nose technology used in this study 
was able to differentiate between VOC profiles of patients with CRC 
F I G U R E  2   Flowchart. AA, advanced adenoma; CRC, colorectal cancer; HP, hyperplastic polyp; N, number; NA, non-advanced adenoma
Number of patients included
for breath testing
N = 511
Breath test without bowel
preparation 
N = 198
Breath test with and without
bowel preparation 
N = 207
Breath test with bowel
preparation 
N = 42

















Newly diagnosed colitis: 5 
Incomplete colonoscopy: 8
Breath sample failure: 51
Dyspnea: 17
Inadequate enclosement mouthpiece: 4
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TA B L E  1   Baseline characteristics
 Control NA AA CRC
N (%)a 128 (28.6) 117 (26.2) 117 (26.2) 70 (15.7)
Male gender, n (%) 66 (51.6) 77 (65.8)b 70 (59.8) 43 (61.4)
Age, y, median (IQR) 62 (56-69) 66 (62-72)b 65 (60-70)b 68 (62-73)b
BMI, median kg/m2 (IQR) 27.4 (24.4-30.1) 26.5 (24.1- 29.5) 27.1 (24.7- 29.6) 26.5 
(23.7- 29.2)
Hypertension, n (%) 47 (36.7) 45 (38.5) 53 (45.2) 36 (51.4)b
Diabetes, n (%) 14 (10.9) 12 (10.3) 19 (16.2) 11 (15.7)
COPD/asthma, n (%) 19 (14.9) 23 (19.7) 11 (9.4)b 4 (5.7)
Abdominal surgery, n (%) 22 (17.2) 19 (16.2) 20 (17.1) 15 (21.4)
Smoking statusc, n (%)
Current 20 (15.6) 23 (19.7) 31 (26.5) 8 (8.6)
Ex-smoker 58 (45.3) 55 (47.0) 51 (43.6) 33 (47.1)
Never smoker 50 (39.1) 39 (33.3) 35 (29.9) 31 (44.3)
Alcohol use in IE/week, median (IQR) 1 (0.0-7.0) 3 (0.0-14.0)b 4 (1.0-14.0)b 1 (0.0-13.0)
Use of antibiotics (≤3 mo before breath testing) 15 (11.7) 19 (16.2) 11 (9.4) (8.6)
PPI use 32 (25.0) 26 (22.2) 33 (28.2) 19 (27.1)
Location most advanced lesion
Proximal  40 (34.2) 29 (24.8) 18 (25.7)
Distal  44 (37.6) 75 (64.1) 52 (74.3)
Both  33 (28.2) 13 (11.1) 0 (0)
Cancer type
Adenocarcinoma    67 (95.7)
Other    3 (4.3)
Stage CRC
Stage I    22 (31.4)
Stage II    22 (31.4)
Stage III    23 (32.9)
Stage IV    3 (4.3)
Cancers and advanced AA
CRC without AA    53 (75.7)
CRC with proximal AA    7 (10.0)
CRC with distal AA    10 (14.3)
Type of AA
≥10 mm   68 (58.1) 8 (47.1)
≥25% villous pathology   11 (9.4) 6 (35.3)
HGD   0 (0) 1 (5.9)
≥10 + HGD   3 (2.6) 0 (0)
≥10 + ≥ 25% villous   31 (26.5) 1 (5.9)
≥10 + ≥ 25% villous + HGD   4 (3.4) 1 (5.9)
Type of NA
1-5mm  140 126 36
6-9mm  100 87 27
Number of HP  28 39 8
Abbreviations: AA, advanced adenoma; CRC, colorectal cancer; IQR, interquartile range; NA, non-advanced adenoma.
aPatients with only hyperplastic polyps are not shown due to small patient numbers (n = 15). 
bSignificance P < 0.05, subgroups were compared with controls to determine significance. 
cEx-smokers were defined as those who had not smoked for at least 6 months before study commencement. 
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and patients with normal colonoscopy with an AUC of 0.84 which in-
dicates that exhaled VOC profiles differ between these patients and 
that these differences can be captured with an e-nose. Furthermore, 
the results of this study also suggest that patients with AA have a 
distinct VOC profile.
In the last decade, multiple proof-of-principle studies have 
demonstrated the efficacy of utilising VOC profiles for clinical di-
agnostics. VOC analysis has not only been used successfully for the 
detection of several types of cancers such as lung,18,19 breast,20,50 
prostate,51,52 gastric and oesophageal cancer,53,54 but also for the 
detection of various endoluminal gastrointestinal diseases like 
IBD,55,56 Helicobacter pylori in the stomach57 and coeliac disease.58 
Furthermore, some studies have also suggested that VOC analysis 
can be used to differentiate between various diseases.18,23,34,39,59 
Although the findings of these studies still need to be validated 
in larger studies, the results seem to support the hypothesis that 
pathological processes in the body have the potential to influ-
ence VOC profiles and that each disease has its own specific VOC 
signature.18-20,23,34,39,50-59
The exact mechanism behind the generation of disease-specific 
VOCs is complex. With regard to CRC-related VOCs it is thought 
that uncontrolled cell growth at the tumour site and systemic re-
sponses associated with carcinogenesis (ie increased catabolism, 
increased oxidative stress and immune activation) contribute to 
the observed changes in VOC profiles.60,61 In addition, there is also 
growing evidence linking the gut microbiome to CRC development 
through interactions with the host’s immune system, production of 
cancer-associated metabolites and release of genotoxic virulence 
factors.62 It is therefore plausible that changes in VOC profiles of 
CRC patients are, at least in part, the result of changes in the gut 
microbiome. Furthermore, concomitant disease, diet-, lifestyle- and 
medication-related factors also have the potential to influence VOC 
profiles, which is why it will take some time before the mechanisms 
behind the generation of CRC-associated VOCs will be clarified.63-66
Meanwhile, the evidence of potential VOCs that might serve 
as biomarkers for CRC is accumulating. Several proof-of-princi-
ple studies have already reported significant differences in VOCs 
between CRC patients and controls using various biological spec-
imens for VOC analysis ie breath,21-24 faeces,25-30 urine31-35 and 
blood.22 These pilot studies reported an AUC for CRC ranging be-
tween 0.67 and 0.98, with a sensitivity and specificity ranging be-
tween 63%-100% and 58%-94% respectively, similar to our study. 
Unfortunately, it is not possible to compare the results of these stud-
ies because some studies used a chemical analytical technique with 
the aim to detect the occurrence, identity and changes in quantities 
of VOCs, while other studies used sensor arrays with pattern recog-
nition technologies with the aim to detect collective differences in 
the chemical composition of all VOCs. Furthermore, the lack of stan-
dardised methods for all phases of VOC analysis further complicates 
comparison of study data even among studies that used the same 
technique for VOC analysis. Nevertheless, the results of these pilot 
studies suggest that CRC has a specific VOC signature which can be 
detected in various biological specimens.21-29,31-35,67
Hitherto, five studies have evaluated the potential of exhaled 
VOCs to serve as a non-invasive biomarker for CRC.21-24,68 GC-MS 
was used in two studies,21,22 one study used an e-nose68 and two 
studies evaluated both techniques23,24 for VOC analysis. All four 
GC-MS studies were able to identify a pattern of discriminatory 
VOCs, consisting of 4-15 VOCs. No single discriminatory VOC could 
be identified which likely reflects the complexity of the metabolic 
derangements and systemic responses associated with CRC.21-24,68 
Interestingly, the VOCs identified differed among studies, which 
may be explained by a combination of differences in patient char-
acteristics, breath sampling methods, storage conditions, GC-MS 
devices and statistical methods used among these studies. Studies 
that evaluated the use of a cross-reactive nanosensor reported an 
AUC of 0.38-0.91 for CRC.23,24,68 Only Altomore and colleagues68 
were unable to detect a significant differences between the ex-
haled VOC profiles of patients with CRC and controls, AUC of 0.38. 
Sensors used in their PEN3 e-nose may have been less sensitive to 
CRC-associated VOCs than sensors used in the other two studies, 
and our study.23,24
Our study also evaluated the ability of VOCs to serve as biomark-
ers for precursor lesions of CRC, since cost-efficacy of screening 
TA B L E  2   Colorectal cancer and Advanced Adenomas versus Controls
Analysisa Cases Controls AUC Sens (%) Spec (%) PPV (%) NPV (%)
CRC vs. controls
Training model 42 68 0.76 83 60 56 85
Blind predictions (validation) 20 36 0.74 80 64 41 85
Final model with all data 62 104 0.84 95 64 61 96
AA vs. controls
Training model 74 68 0.71 82 59 69 75
Blind predictions (validation) 38 36 0.61 67 45 69 59
Final model with all data 112 104 0.73 79 59 67 73
Abbreviations: AA, Advanced adenomas; AUC, area under the curve; CRC, colorectal cancer; NPV, negative predictive value; PPV, positive predictive 
value; Sens, sensitivity; Spec, specificity; vs, versus.
aThese analysis only included breath tests performed before the bowel preparation. 
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F I G U R E  3   ROC curve plus scatter plot of the final disease-specific model for colorectal cancer (CRC). In the scatter plot the individual 
e-nose value of each patient and control is plotted. Patients with histopathologically confirmed CRC are represented with a red square and 
all healthy controls are represented with a green dot. The blue line at −0.03 indicates the cut-off point used in this study. All patients with a 
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programs for CRC could significantly improve if a non-invasive test 
would be able to accurately detect these lesions to prevent the de-
velopment of CRC. The e-nose used in this study was able to detect 
AAs with an AUC of 0.73, which is in line with the study of de Meij 
et al,29 who reported an AUC of 0.79 for the detection of AAs using 
faecal samples. Three other studies were unable to differentiate 
between patients with AAs and controls using faecal25 and urinary 
samples32,33 for VOC analysis. Contrary to our results, de Meij et 
al29 were also able to differentiate between CRC and AA with their 
e-nose (Cyranose 320), which may be explained by differences in 
biological specimens used, sensor selection, statistical methods and 
pathological tumour stages. Furthermore, we were able to distin-
guish CRCs from NAs, but it was not possible to differentiate AAs 
from NAs. We therefore hypothesise that VOCs associated with AAs 
with villous features and/or high-grade dysplasia may be more sim-
ilar to CRC-associated VOCs while AAs without these features may 
be more similar to NAs. Nevertheless, this hypothesis still needs to 
be investigated in a larger study.
Co-morbidities, lifestyle factors, such as smoking, BMI and use of 
antibiotics and/or PPIs were equally matched between patient groups 
and did not seem to influence accuracy of the blind predictions. In 
addition, control patients with a history of polypectomy were mis-
classified as AAs in 20%, but larger studies should further evaluate 
the influence of polypectomy on VOC mixtures. The influence of 
bowel preparation was also addressed in this study, because bowel 
preparation could potentially alter the gut microbiome and thereby 
influence VOC profiles. Leja et al69 already evaluated the influence 
of bowel preparation on VOC profiles and only reported a significant 
increase in acetone levels which may have been a consequence of 
fasting. We were able to detect a collective difference in VOC pro-
files of all patients before and after bowel preparation, but only with 
a moderate accuracy of 0.72. In the control group, bowel prepara-
tion was detected with the highest accuracy, AUC of 0.82. However, 
e-nose technology does not allow for the identification of specific 
VOCs which is why we can only speculate that these differences 
reflect dietary restrictions and/or use of laxatives. Nonetheless, it 
is reassuring that fasting did not seem to influence the accuracy of 
the disease models (P = 0.45 for CRC and P = 0.84 for AA-model) 
since this will make the implementation of breath analysis in clinical 
practice easier.
This study has several strengths. All consecutive adult colonos-
copy patients were invited for study participation in two different 
TA B L E  3   Baseline characteristics blind validation group
 
CRC versus controls AA versus controls
Correctly 
predicted (n = 39)
Incorrectly 
predicted (n = 17) P-value
Correctly 
predicted (n = 41)
Incorrectly 
predicted (n = 33) P-value
Male 23 (59.0) 11 (64.7) 0.69 23 (56.1%) 22 (66.7%) 0.36
Age, median, IQR 64 (59-73) 65 (59-71) 0.93 63 (58-71) 65 (59-70) 0.73
BMI, median, IQR 26.7 (23.5-29.1) 27.5 (24.6-31.0) 0.40 27.3 (24.3-28.9) 26.2 (23.5-30.4) 0.72
Hypertension 21 (53.8) 10 (58.8) 0.73 17 (41.5)) 17 (51.5) 0.39
Diabetes 4 (10.3) 2 (11.7) 0.87 7 (17.1) 4 (12.1) 0.55
COPD/Asthma 5 (12.8) 0 (0) 0.12 4 (9.8) 2 (6.1) 0.56
Cardiac failure (NYHA≥3) 0 (0) 0 (0) N/A 0 (0) 0 (0) N/A
Abdominal surgerya 10 (25.6) 6 (35.3) 0.46 12 (29.3) 8 (24.2) 0.58
Current smoker 5 (12.8) 3 (17.6) 0.64 12 (29.3) 7 (21.2) 0.43
Pack years, median, IQR 3.2 (0-14.0) 7.5 (0.1-14.7) 0.33 10 (0-25.5) 9 (7.8-17.3) 0.25
Alcohol use, median, IQR 1 (0-6) 1 (0-7) 0.83 2 (0-6) 4 (0-14) 0.23
Use of antibioticsb 2 (5.1) 2 (11.8) 0.38 3 (7.3) 2 (6.1) 0.83
PPI use 13 (33.3) 5 (39.4) 0.77 16 (39.0) 10 (30.3) 0.44
Previous polypectomy 4 (10.3) 2 (11.8) 0.87 7 (17.1) 3 (9.1) 0.32
Last meal (<3 h) 21 (54.8) 11 (64.7) 0.45 27 (65.9) 21 (63.6) 0.84
Time of measurement (n = 28) (n = 28)  (n = 37) (n = 37)  
First half 21 (75.0) 7 (25.0) 0.38 17 (45.9) 20 (54.1) 0.10
Second half 18 (64.3) 10 (58.8)  24 (64.9) 13 (35.1)  
CRC stage
Stage I-II 8 4 0.07    
Stage II-III 8 0     
Abbreviations: AA, advanced adenomas; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRC, colorectal cancer; IQR, 
interquartile range; n, number; NYHA, New York Hart association classification; PPI, Proton pump inhibitor.
aAbdominal surgery does not include (partial) colon resection as those patients were excluded in our study. 
bUse of antibiotics within 3 mo prior to study inclusion. 
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hospitals to improve generalisability of the results. All diagnoses 
were double checked to avoid misclassification and the results were 
blindly validated in new study patients, which yielded similar results 
suggesting potential reproducibility of the results. In addition, we 
were able to exchange disease models between e-noses of the same 
brand which will render extensive training of individual e-noses un-
necessary which can accelerate implementation of e-nose technol-
ogy in clinical practice.
Some limitations of our study should also be indicated. Most im-
portantly, the number of failed breath tests, almost 10%, raises con-
cern regarding the feasibility of the breath sampling technique used. 
However, our breathing protocol may have been too strict since 
other studies using the same e-nose did not report such high failure 
rates,38-47,70-72 neither in children with severe asthma or cystic fibro-
sis (<2%),72 nor in adult patients with acute exacerbation of chronic 
obstructive pulmonary disease (0%).71 In this study, two-thirds of the 
failed tests were suboptimal tests; ie interrupted tests by talking, 
laughing, coughing or inappropriate enclosement of the mouthpiece. 
In clinical practice these suboptimal tests can be repeated imme-
diately (this was not allowed in our study) and additional training 
of research nurses may further reduce the number of failed tests. 
Nonetheless, the results of this study do underline the importance 
of an objective tool to evaluate the quality of breath samples before 
clinical implementation of breath analysis is considered. Another 
limitation of our study was the use of an imperfect reference test, 
up to 25% of all polyps are still missed with conventional colonos-
copy, which may have led to misclassification of patients limiting 
the discriminatory power of the developed algorithms.73 In addition, 
this study did not collect information on medication use, but only 
evaluated the presence of co-morbidities between patient groups. 
Other study limitations are inherent to e-nose technology such as 
potential reproducibility issues, sensor drift, instrument variability 
and loss of sensitivity in the presence of alcohol which need to be 
addressed in further studies.74 Nevertheless, in this study five differ-
ent e-noses were used and accuracy of the training models did not 
change over time suggesting that inter-device variability and sensor 
drift were minimal. In addition, sensors used in our e-nose have a 
proven track record in terms of stability and lifetime in other sectors 
(ie automotive).75
Future studies in the field of VOC analysis should focus on 
standardising all phases of VOC analysis among different gas 
analysis techniques to obtain a translatable approach for future 
VOC research; ie standardisation of gas analysis instruments, 
sampling protocols, statistical methods, etc. Large scale studies 
are required to evaluate the influence of covariates on VOC pro-
files (eg co-morbidities, medication use, lifestyle factors) and to 
TA B L E  4   Secondary outcomes
Analysisa Cases (n) Control (n) AUC Sens (%) Spec (%) PPV (%) NPV (%)
CRC vs NA 62 112 0.85 90 65 59 92
CRC vs NA + HP 62 127 0.91 98 52 50 98
CRC vs AA 62 112 No model No model No model No model No model
CRC vs AA + NA + HP 62 239 No model No model No model No model No model
CRC vs AA + NA + HP + Control 62 343 No model No model No model No model No model
CRC + AA vs Control 174 104 0.72 83 54 75 66
CRC + AA vs NA + HP + Control 174 343 No model No model No model No model No model
AA vs NA 112 112 No model No model No model No model No model
NA vs Control 112 104 0.72 67 64 67 64
AA + NA vs Control 224 104 No model No model No model No model No model
Bowel preparationb
Control before vs after bowel prep 59 59 0.82 77 70 0.72 0.76
AA before vs after bowel prep 56c 56c 0.70 80 59 68 73
CRC before vs after bowel prep 19 19 No model No model No model No model No model
All patients with two breath tests before and 
after bowel prep
203c 203c 0.72 65 74 71 68
All CRC breath tests versus all Control 
breath testsd
89 187 0.76 88 71 59 92
Abbreviations: AA, advanced adenomas; AUC, area under the curve; C, controls; CRC, colorectal cancer; n, number; NA, non-advanced adenomas; 
NPV, negative predictive value; PPV, positive predictive value; Sens, sensitivity; Spec, specificity; vs, versus.
aThis analysis only included breath tests performed before the bowel preparation. 
bThis analysis included all patients with an adequate breath test performed before and after bowel preparation. 
cFour patients with advanced adenomas did not have an adequate before and after breath test. 
dThis analysis included all of the breath tests of CRC patients and Controls. This means that if CRC patients or controls performed two breath tests 
then both tests were included (see flowchart). 
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explore the full diagnostic potential of VOC analysis, preferably 
with external validation. Eventually, the use of different biological 
samples and techniques for VOC analysis should be compared to 
evaluate feasibility, reliability and cost-effectiveness of the differ-
ent methods of VOC analysis. In this respect, breath analysis with 
e-nose technology might be preferred over other biological spec-
imens and use of chemical analytical techniques because e-nose 
devices are relatively low-cost, easily operated and have the po-
tential for a point-of-care diagnosis which makes them more suit-
able for clinical practice. In addition, breath tests may have high 
acceptability among patients improving adherence to CRC screen-
ing programs.
In conclusion, this multicentre study suggests that breath anal-
ysis using e-nose technology has the potential to serve as an easy-
to-use, non-invasive diagnostic tool for the detection of CRC and its 
precursor lesions.
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